Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
NCT ID: NCT01559038
Last Updated: 2020-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
483 participants
OBSERVATIONAL
2012-02-16
2019-11-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adalimumab
Responding to treatment with non-biologic DMARDs (disease-modifying antirheumatic drugs) and initiated on treatment with adalimumab as monotherapy or in combination with other medications
No interventions assigned to this group
DMARD (disease-modifying antirheumatic drugs)
Initiated on non-biologic DMARD(disease-modifying antirheumatic drugs) or requiring switching to another non biologic DMARD (disease-modifying antirheumatic drugs) as monotherapy, or in combination with other medications
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
* Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as well as active psoriatic skin lesions or confirmed history of psoriasis
* Inadequate response or non-tolerant to current disease-modifying antirheumatic drugs (DMARD) based treatment for PsA
Exclusion Criteria
* Patient cannot or will not sign informed consent
* Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated
* Previous treatment with anti-tumor necrosis factor (anti-TNF) or other biologic agent
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cato Research
INDUSTRY
JSS Medical Research Inc.
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pont, Cranbrook, BC, CA /ID# 69120
Cranbrook, British Columbia, Canada
Dr. Barbara T. Blumenauer Inc. /ID# 75393
Kamloops, British Columbia, Canada
Hudson, Kamloops, Canada /ID# 69104
Kamloops, British Columbia, Canada
Dr. Maqbool R. Sheriff Inc. /ID# 69125
Nanaimo, British Columbia, Canada
Carmi Medical Clinic /ID# 69128
Penticton, British Columbia, Canada
Dr. J. Antonio Avina-Zubieta /ID# 71035
Richmond, British Columbia, Canada
Dr. Alfonso Verdejo Inc. /ID# 69131
Vancouver, British Columbia, Canada
Dr. Milton F. Baker Inc. /ID# 69085
Victoria, British Columbia, Canada
Manitoba Clinic /ID# 69113
Winnipeg, Manitoba, Canada
Nexus Clinical Research /ID# 45622
St. John's, Newfoundland and Labrador, Canada
St. Clare's Mercy Hospital /ID# 69121
St. John's, Newfoundland and Labrador, Canada
Qe Ii Hsc /Id# 69129
Halifax, Nova Scotia, Canada
Dr. Juris Lazovskis Inc. /ID# 69111
Sydney, Nova Scotia, Canada
Waterside Clinique /ID# 72173
Barrie, Ontario, Canada
Shickh, Bowmanville, Canada /ID# 90513
Bowmanville, Ontario, Canada
Brockville Medical Center /ID# 69105
Brockville, Ontario, Canada
Dr. Sanjay Dixit Medicine Professional Corporation /ID# 69092
Burlington, Ontario, Canada
Dr. Chrisotomor Kouroukis & Dr /ID# 137894
Dundas, Ontario, Canada
Charlton Medical Centre /ID# 133073
Hamilton, Ontario, Canada
Charlton Medical Centre /ID# 69122
Hamilton, Ontario, Canada
Dr. William G. Bensen Centre /ID# 69086
Hamilton, Ontario, Canada
West Mountain Medical Center /ID# 128878
Hamilton, Ontario, Canada
Lynderm Research Inc. /ID# 76736
Markham, Ontario, Canada
Brandusa Florica Med Prof Corp /ID# 81876
Mississauga, Ontario, Canada
Credit Valley Rheumatology /ID# 69089
Mississauga, Ontario, Canada
Imtiaz MS Khan Medicine Prof /ID# 69110
Mississauga, Ontario, Canada
Rajwinder S. Dhillon Medicine /ID# 138672
Niagara Falls, Ontario, Canada
Davis, Ottawa, CA /ID# 69091
Ottawa, Ontario, Canada
Setty, Owen Sound, CA /ID# 69123
Owen Sound, Ontario, Canada
York Dermatology Clinic and Research Centre /ID# 127943
Richmond Hill, Ontario, Canada
Pedvis Med Prof Corp /ID# 69388
Toronto, Ontario, Canada
Jonathan Stein Med Prof Corp /ID# 71134
Toronto, Ontario, Canada
Karasik, Toronto, CA /ID# 69109
Toronto, Ontario, Canada
Institut de Rhum. de Montreal /ID# 69100
Montreal, Quebec, Canada
PSS Medical Inc. /ID# 69127
Montreal, Quebec, Canada
Couture, Outremont, CA /ID# 69090
Outremont, Quebec, Canada
Ctr. de Rheum de l'est du QC /ID# 69097
Rimouski, Quebec, Canada
Groupe de Recherche en Maladies Osseuses /ID# 69087
Sainte-Foy, Quebec, Canada
CHUS - Hopital Fleurimont /ID# 94735
Sherbrooke, Quebec, Canada
Ctr. de Recherche Musculo-Sque /ID# 69112
Trois-Rivières, Quebec, Canada
Rheum Disease Ctr of Montreal /ID# 143964
Westmount, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khraishi MM, Remple VP, Silverberg S, Stewart JC, Florica B, Bessette L. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs. J Rheumatol. 2022 May;49(5):454-464. doi: 10.3899/jrheum.200609. Epub 2022 Jan 15.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P12-666
Identifier Type: -
Identifier Source: org_study_id